ABCL
Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
$3.82
-8.17% today
Updated 2026-04-29
Market cap
$1.16B
P/E ratio
—
P/S ratio
15.41x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$2 – $7
Volume
4.0M
Abcellera Biologics Inc (ABCL) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+17.4%
Last 4 quarters
Revenue YoY growth
+788.2%
Most recent quarter
EPS YoY growth
+75.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.7%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-16.6%
2025-11-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-24 | $-0.03 | +79.2% | $3.03 | $3.19 | +5.3% |
| 2025-11-06 | $-0.19 | -35.7% | $4.69 | $3.91 | -16.6% |
| 2025-08-07 | $-0.12 | +14.3% | $4.12 | $4.25 | +3.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.14 | $-0.03 | +79.2% | $44.85M | +788.2% |
| 2025-09-30 | $-0.14 | $-0.19 | -35.7% | $8.96M | +37.6% |
| 2025-06-30 | $-0.14 | $-0.12 | +14.3% | $17.08M | +133.3% |
| 2025-03-31 | $-0.17 | $-0.15 | +11.8% | $4.24M | -57.5% |
| 2024-12-31 | $-0.15 | $-0.12 | +18.4% | $5.05M | -45.0% |
| 2024-09-30 | $-0.15 | $-0.17 | -13.3% | $6.51M | -1.4% |
| 2024-06-30 | $-0.14 | $-0.13 | +7.1% | $7.32M | -27.2% |
| 2024-03-31 | $-0.17 | $-0.14 | +17.6% | $9.95M | — |
| 2023-12-31 | $-0.13 | $-0.17 | -30.8% | $9.18M | — |
| 2023-09-30 | $-0.13 | $-0.10 | +23.1% | $6.60M | — |
| 2023-06-30 | $-0.13 | $-0.11 | +15.4% | $10.06M | — |
Frequently asked questions
Has Abcellera Biologics Inc beaten earnings estimates?
Abcellera Biologics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +17.4% over the last 4 quarters.
How does ABCL stock react to earnings?
ABCL stock has moved an average of -2.7% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Abcellera Biologics Inc's revenue growth rate?
Abcellera Biologics Inc reported year-over-year revenue growth of +788.2% in its most recent quarter, with EPS growing +75.0% year-over-year.